Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Income: 2018-2025

Historic Net Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' Net Income fell 94.81% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.57%. This contributed to the annual value of -$80.9 million for FY2024, which is 172.30% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Net Income of -$13.4 million as of Q3 2025, which was down 46.49% from -$9.2 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Net Income ranged from a high of $118.6 million in Q4 2022 and a low of -$57.7 million during Q1 2021.
  • For the 3-year period, Arcturus Therapeutics Holdings' Net Income averaged around -$13.4 million, with its median value being -$14.1 million (2025).
  • In the last 5 years, Arcturus Therapeutics Holdings' Net Income slumped by 509.45% in 2021 and then skyrocketed by 415.16% in 2022.
  • Arcturus Therapeutics Holdings' Net Income (Quarterly) stood at -$37.6 million in 2021, then soared by 415.16% to $118.6 million in 2022, then crashed by 109.84% to -$11.7 million in 2023, then plummeted by 156.89% to -$30.0 million in 2024, then slumped by 94.81% to -$13.4 million in 2025.
  • Its Net Income was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.